A randomised controlled trial of antenatal melatonin supplementation in fetal growth restriction for fetal neuroprotection.
- Conditions
- Fetal Growth Restriction (FGR)Fetal NeuroprotectionReproductive Health and Childbirth - Fetal medicine and complications of pregnancyNeurological - Other neurological disorders
- Registration Number
- ACTRN12617001515381
- Lead Sponsor
- Monash Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 336
1) Women, with a singleton pregnancy
2) Severe fetal growth restriction (FGR), defined as:
Estimated fetal weight equal to, or less than, 3rd centile for gestational age according to charts from Mikolajczyk et al (2011) or an estimated fetal weight that is less than the 10th centile (Mikolajcyk et al 2011) in combination with at least one abnormal fetoplacental doppler study, these being:
-Uterine artery (raised pulsatility index equal to, or more than, 95th centile)
-Umbilical artery (pulsatility index equal to, or more than, 95th centile or absent/reversed end-diastolic flow)
-Ductus venosus (abnormal A wave and/or pulsatility index equal to, or more than, 95th centile)
3) Gestation: (confirmed) 23+0 to 31+6 weeks’
4) Age: 18 years or more
5) Understands English
Reference: Mikolajczyk, R.T., et al., A global reference for fetal-weight and birthweight percentiles. Lancet, 2011. 377 (9780): pp. 1855-61
1) A fetus with a known chromosomal, major structural anomaly or non-placental cause of fetal growth restriction
2) Pregnancies requiring immediate delivery (eg absent A wave in ductus venosus, preterminal CTG or biophysical profile)
3) Co-recruitment in another clinical trial where a pharmaceutical product or nutritional supplement is the trial intervention.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method